The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 15, 2018

Filed:

Jul. 29, 2013
Applicant:

Gtx, Inc., Memphis, TN (US);

Inventors:

James T. Dalton, Lakeland, TN (US);

Mitchell S. Steiner, Germantown, TN (US);

Ramesh Narayanan, Cordova, TN (US);

Sunjoo Ahn, Daejeon, KR;

Assignee:

GTX, INC., Memphis, TN (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/167 (2006.01); C07C 255/60 (2006.01); C07C 237/20 (2006.01);
U.S. Cl.
CPC ...
C07C 255/60 (2013.01); A61K 31/167 (2013.01); C07C 237/20 (2013.01);
Abstract

This invention relates to the treatment of breast cancer in a subject, for example a female subject. The breast cancer includes metastatic breast cancer, refractory breast cancer, AR-positive breast cancer, AR-positive refractory breast cancer, AR-positive metastatic breast cancer, AR-positive and ER-positive breast cancer, triple negative breast cancer, advanced breast cancer, breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments, and metastasis in a subject suffering from breast cancer. The method comprises administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.


Find Patent Forward Citations

Loading…